Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Background Ketamine appears to have a therapeutic role in certain mental disorders, most
notably depression. However, the comparative performance of different formulations of …

Major depressive disorder (MDD), also referred to as depression, is one of the most common
psychiatric disorders with a high economic burden. The etiology of depression is still not …

The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor
(NMDAR) antagonist (R, S)-ketamine has been a crucial breakthrough in mood disorder …

Background Ketamine is established as a rapid and effective treatment in adults with
treatment-resistant depression (TRD). The availability of different formulations and routes of …

We aimed to analyze the efficacy and safety of arketamine, the R (−)-enantiomer of
ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven …

Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist first developed as an
anesthetic, has shown significant promise as a medication with rapid antidepressant …

The efficacy of standard antidepressants is limited for many patients with mood disorders
such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent …

Background Intranasal esketamine has received regulatory approvals for the treatment of
depression. Recently a large trial of repeated dose racemic ketamine also demonstrated …

The robust antidepressant effects of (R, S)-ketamine are among the most important
discoveries in mood research over the last half century. Off-label use of (R, S)-ketamine …